Appili Shares Advance After FDA Accepts NDA for ATI-1501
08 Februar 2023 - 5:31PM
Dow Jones News
By Robb M. Stewart
Appili Therapeutics Inc.'s shares climbed Wednesday after the
biopharmaceutical company said its new drug application for a
liquid oral reformulation of the antibiotic metronidazole was
accepted by the U.S. Food and Drug Administration.
In morning trading, the shares were up 10% at C$0.06, extending
the run higher so far this year to 22%.
The FDA's acceptance of the application for ATI-1501, which has
been licensed to Saptalis Pharmaceuticals LLC, is a step toward
bringing the drug to market. The agency has set a Prescription Drug
User Fee action data of Sept. 23, Appili said.
The company said it is working with New York-based Saptalis on
supporting the review process and responding to questions from the
FDA.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
February 08, 2023 11:16 ET (16:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Apr 2023 bis Apr 2024